Form 4: Janux Therapeutics CEO Sells 5,000 Shares Under 10b5-1 Trading Plan

Janux Therapeutics CEO, David Alan Campbell, sold 5,000 shares of common stock at an average price of $60.0008 per share under a pre-arranged 10b5-1 trading plan.

Summary

• David Alan Campbell, the President and CEO of Janux Therapeutics, sold 5,000 shares of the company's common stock on January 7, 2025.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 21, 2024.
• The weighted average sale price was $60.0008 per share, with prices ranging from $60.00 to $60.02.
• Following the transaction, Mr. Campbell directly owns 293,054 shares of Janux Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, with no indication of positive or negative sentiment.

Risks

• Sales by company insiders can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Insider trading activity is a common occurrence in publicly traded companies, and sales under a 10b5-1 plan are generally viewed as pre-planned and not necessarily indicative of a change in the executive's outlook on the company.

Comparison to Industry Standards

• Sales by executives under 10b5-1 plans are a common practice across the industry, used to avoid accusations of insider trading.
• The volume of shares sold is relatively small compared to the total outstanding shares of the company, which is typical for such transactions.
• The price range of the sale is within a tight band, indicating a stable market price at the time of the transaction.

Stakeholder Impact

• The sale may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's operations or financial position.

Key Dates

Keywords

Janux Therapeutics, David Alan Campbell, insider trading, stock sale, Rule 10b5-1, executive, share transaction